How should I manage a patient with normal CBC and chemistry but borderline low iron studies (low serum iron, normal TIBC, transferrin saturation 18%, ferritin 33 ng/mL) and vitamin D deficiency (25‑OH‑vitamin D 18 ng/mL)?

Management of Iron Deficiency Without Anemia and Vitamin D Deficiency

This patient has iron deficiency without anemia (ferritin 33 ng/mL, transferrin saturation 18%) and vitamin D deficiency (25-OH-vitamin D 18 ng/mL), both of which require treatment to prevent progression and optimize quality of life.

Iron Status Assessment

Your patient's iron studies reveal:

• Ferritin 33 ng/mL: Below the 45 μg/L threshold that provides optimal sensitivity for iron deficiency 1
• Transferrin saturation 18%: Below the 20% cutoff used to define iron deficiency in multiple conditions 1
• Normal hemoglobin (13.0 g/dL): This is non-anemic iron deficiency

While the British Society of Gastroenterology guidelines focus primarily on iron deficiency anemia, they acknowledge that ferritin <45 μg/L warrants consideration for intervention, especially with transferrin saturation <20% 1. Recent evidence confirms that iron deficiency without anemia causes significant symptoms including fatigue, impaired concentration, and reduced exercise tolerance 2.

Iron Deficiency Management

Start oral iron supplementation with 28-50 mg elemental iron daily 3. This dosing range optimizes compliance by minimizing gastrointestinal side effects while providing adequate repletion.

Specific approach:

• First-line: Oral iron (ferrous sulfate 325 mg contains ~65 mg elemental iron; give every other day or daily based on tolerance)
• Dietary counseling: Increase heme iron intake, consume with vitamin C enhancers, avoid calcium/tea/coffee inhibitors around iron dosing
• Recheck labs in 8-10 weeks: Repeat CBC, ferritin, transferrin saturation 3
• Target: Ferritin >30 μg/L (ideally >50 μg/L for sustained stores) and transferrin saturation >20%

Investigation considerations:

Even without anemia, investigate for underlying causes:

• Menstrual history: Heavy or prolonged bleeding is the most common cause in premenopausal women
• Dietary assessment: Vegetarian/vegan diet, eating disorders
• GI symptoms: If present, consider celiac serology and H. pylori testing 2
• Bidirectional endoscopy: Generally reserved for those with anemia or concerning GI symptoms, not routinely needed for non-anemic iron deficiency in young women with clear menstrual losses

Important caveat: The guidelines note that intravenous iron is only indicated if oral iron fails, is not tolerated, or in specific conditions like chronic heart failure or inflammatory bowel disease 1. Your patient should trial oral iron first.

Vitamin D Deficiency Management

Treat with 2000 IU daily of vitamin D3 (or 50,000 IU weekly) for at least 6 weeks, then maintain with 600-1000 IU daily 4.

Your patient's 25-OH-vitamin D of 18 ng/mL represents deficiency (normal >30 ng/mL). The Endocrine Society guideline provides clear dosing:

• Loading phase: 2000 IU/day for 6+ weeks OR 50,000 IU once weekly for 6+ weeks
• Expected rise: ~0.4 ng/mL per 100 IU daily, so 2000 IU should increase levels by ~8 ng/mL
• Maintenance: 600-1000 IU daily once replete 4
• Recheck level: After 8-12 weeks of treatment

Monitoring considerations:

• Vitamin D can be taken with or without food (does not require dietary fat) 4
• Monitor calcium if using higher doses, though hypercalcemia is rare at these therapeutic levels
• No need to check calcium/PTH unless symptomatic

The Iron-Vitamin D Connection

Emerging evidence suggests vitamin D deficiency may worsen iron status through effects on erythropoiesis and iron metabolism 5. While this relationship is still being characterized, treating both deficiencies simultaneously is appropriate and may have synergistic benefits.

Follow-Up Algorithm

At 8-10 weeks:

1. Recheck CBC, ferritin, transferrin saturation, 25-OH-vitamin D
2. If ferritin remains <30 ng/mL despite compliance: Consider GI evaluation or switch to intravenous iron
3. If vitamin D remains <30 ng/mL: Continue loading dose for another 6 weeks
4. Once replete: Transition to maintenance dosing

Long-term (every 6-12 months):

• Monitor ferritin in patients with ongoing risk factors (heavy menses, dietary restrictions)
• Intermittent oral iron supplementation may be needed to maintain stores 3

Critical pitfall to avoid:

Do not ignore non-anemic iron deficiency. The traditional focus on hemoglobin thresholds causes underdiagnosis, particularly in menstruating women 2. Your patient's symptoms (if present—fatigue, reduced exercise tolerance, cognitive issues) will improve with iron repletion even though she is not anemic.